198 related articles for article (PubMed ID: 23611195)
1. Bayesian adaptive D-optimal design with delayed responses.
Li J; Fu H
J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
[TBL] [Abstract][Full Text] [Related]
2. Bayesian optimal adaptive designs for delayed-response dose-finding studies.
Li W; Fu H
J Biopharm Stat; 2011 Sep; 21(5):888-901. PubMed ID: 21830921
[TBL] [Abstract][Full Text] [Related]
3. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
4. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
5. Seamless Phase II/III combination study through response adaptive randomization.
Wang L; Cui L
J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
[TBL] [Abstract][Full Text] [Related]
6. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
8. Time-to-event analysis with treatment arm selection at interim.
Di Scala L; Glimm E
Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
[TBL] [Abstract][Full Text] [Related]
9. A bayesian dose-finding design adapting to efficacy and tolerability response.
Padmanabhan SK; Berry S; Dragalin V; Krams M
J Biopharm Stat; 2012; 22(2):276-93. PubMed ID: 22251174
[TBL] [Abstract][Full Text] [Related]
10. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
[TBL] [Abstract][Full Text] [Related]
11. Adaptive sequential testing for multiple comparisons.
Gao P; Liu L; Mehta C
J Biopharm Stat; 2014; 24(5):1035-58. PubMed ID: 24926848
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian design and analysis for dose-response using informative prior information.
Smith MK; Marshall S
J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
[TBL] [Abstract][Full Text] [Related]
13. A case study of model-based Bayesian dose response estimation.
Tan H; Gruben D; French J; Thomas N
Stat Med; 2011 Sep; 30(21):2622-33. PubMed ID: 21713966
[TBL] [Abstract][Full Text] [Related]
14. Bayesian optimal designs for a quantal dose-response study with potentially missing observations.
Baek I; Zhu W; Wu X; Wong WK
J Biopharm Stat; 2006; 16(5):679-93. PubMed ID: 17037265
[TBL] [Abstract][Full Text] [Related]
15. Bayesian adaptive dose-finding studies with delayed responses.
Fu H; Manner D
J Biopharm Stat; 2010 Sep; 20(5):1055-70. PubMed ID: 20721791
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
Morita S; Yamamoto H; Sugitani Y
Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
[TBL] [Abstract][Full Text] [Related]
17. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
Zhu H
J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
[TBL] [Abstract][Full Text] [Related]
18. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
Thomas N
J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
[TBL] [Abstract][Full Text] [Related]
19. Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.
Ibrahim JG; Chen MH; Xia HA; Liu T
Biometrics; 2012 Jun; 68(2):578-86. PubMed ID: 21955084
[TBL] [Abstract][Full Text] [Related]
20. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
Zohar S; Chevret S
J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
